$Invesco QQQ(QQQ)$ The detail

$Invesco QQQ(QQQ)$ The detail I'm watching in $Ruanyun Edai Technology Inc.(RYET)$ is the 10% royalty on qualifying technology receipts. The signed BioNexus agreement would license Cogni AI exclusively for Malaysian healthcare on closing, which gives the AI expansion story a named partner, a specific market, and defined commercial terms. I'm bullish on that direction. Now I want to see closing, deployments, and royalty-generating activity. Those are the milestones that could strengthen the thesis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":615403818971680,"tweetId":"615403818971680","gmtCreate":1791221555000,"gmtModify":1791252176507,"author":{"id":9000000000000136,"idStr":"9000000000000136","authorId":9000000000000136,"authorIdStr":"9000000000000136","name":"JimmyTurner","avatar":"https://static.tigerbbs.com/9412ae10bafb07946890558126185d43","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":161,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/a86d2c00650348f6b2a24441eeb5fddb","width":"1284","height":"899"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/a86d2c00650348f6b2a24441eeb5fddb","width":"1284","height":"899"}],"title":"","html":"<html><head></head><body><a href=\"https://ttm.financial/S/QQQ\">$Invesco QQQ(QQQ)$&nbsp;</a>The detail I'm watching in <a href=\"https://ttm.financial/S/RYET\">$Ruanyun Edai Technology Inc.(RYET)$&nbsp;</a> is the 10% royalty on qualifying technology receipts. The signed BioNexus agreement would license Cogni AI exclusively for Malaysian healthcare on closing, which gives the AI expansion story a named partner, a specific market, and defined commercial terms. I'm bullish on that direction. Now I want to see closing, deployments, and royalty-generating activity. Those are the milestones that could strengthen the thesis.\n<img src=\"https://community-static.tradeup.com/news/a86d2c00650348f6b2a24441eeb5fddb\" tg-width=\"1284\" tg-height=\"899\"></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/QQQ\">$Invesco QQQ(QQQ)$&nbsp;</a>The detail I'm watching in <a href=\"https://ttm.financial/S/RYET\">$Ruanyun Edai Technology Inc.(RYET)$&nbsp;</a> is the 10% royalty on qualifying technology receipts. The signed BioNexus agreement would license Cogni AI exclusively for Malaysian healthcare on closing, which gives the AI expansion story a named partner, a specific market, and defined commercial terms. I'm bullish on that direction. Now I want to see closing, deployments, and royalty-generating activity. Those are the milestones that could strengthen the thesis.\n<img src=\"https://community-static.tradeup.com/news/a86d2c00650348f6b2a24441eeb5fddb\" tg-width=\"1284\" tg-height=\"899\"></body></html>","text":"$Invesco QQQ(QQQ)$ The detail I'm watching in $Ruanyun Edai Technology Inc.(RYET)$ is the 10% royalty on qualifying technology receipts. The signed BioNexus agreement would license Cogni AI exclusively for Malaysian healthcare on closing, which gives the AI expansion story a named partner, a specific market, and defined commercial terms. I'm bullish on that direction. Now I want to see closing, deployments, and royalty-generating activity. Those are the milestones that could strengthen the thesis.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/615403818971680","repostId":0,"isVote":1,"tweetType":1,"viewCount":50,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["QQQ","RYET"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":430,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/615403818971680"}